Asset sale Completed
J. Molner acquisition of US generic and specialty pharmaceutical product portfolio of Nordic Pharma
Announced Jun 2026 (approx.)
Advisers
US generic and specialty pharmaceutical product portfolio of Nordic Pharma
Target
Not disclosed
J. Molner
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- US generic and specialty pharmaceutical product portfolio of Nordic Pharma
- Acquirer
- J. Molner
- Seller
- Nordic Pharma
- Target based in
- United States
- Buyer based in
- United States (unverified)
- Seller based in
- France (unverified)
- Completed
- Jun 2026
- Sector
- Pharma
In the league tables
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Gilead acquisition of HCXT-2001 (investigational oral IL-23R inhibitor) Oct 2026 · Pharma
- US WorldMeds acquisition of Orbus Therapeutics Oct 2026 · Pharma
- DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon Sep 2026 · US$316m · Specialty finance and leasing
- Grünenthal acquisition of Stivarga (regorafenib) Sep 2026 · US$433m · Pharma
